Pioneering Research to Optimize Pre-exposure Prophylaxis (PrEP) Expansion with Lenacapavir (LEN)

Brief description of study

The purpose of this study is to gather information about how individuals decide if and when to use pre exposure prophylaxis (PrEP) for Human immunodeficiency virus (HIV) prevention over a 2-year period, and when they do, how consistently individuals stay on PrEP, like Lenacapavir (LEN). This study is observational, and will include participants who are on LEN, other PrEP formulations, and who choose not to use PrEP. Visits will occur at the NYC Health + Hospitals/Bellevue Pride Center.

Clinical Study Identifier: s25-01740

ClinicalTrials.gov Identifier: NCT07473778

Principal Investigator: Robert Anwar Pitts.

Other Investigators: Robert James Ulrich, Angelica Cifuentes Kottkamp.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies